COVID-19 vaccine trials must include helminth-infected cohorts.

Egwang, Thomas G; Owalla, Tonny Jimmy; Kemigisha, Margaret

Egwang, Thomas G; Owalla, Tonny Jimmy; Kemigisha, Margaret.

Egwang TG; Med Biotech Laboratories, Kampala, Uganda. tgegwang@gmail.com.
Owalla TJ; Med Biotech Laboratories, Kampala, Uganda.
Kemigisha M; Kiruddu Referral Hospital, Kampala, Uganda.

Nat Immunol ; 23(2): 148, 2022 02.

Article in English | MEDLINE | ID: covidwho-1648855

Subject(s)

COVID-19 Vaccines/administration & dosage; COVID-19/prevention & control; Clinical Trials as Topic; Helminthiasis/immunology; Helminths/immunology; Research Design; SARS-CoV-2/immunology; Vaccine Development; Africa/epidemiology; Animals; COVID-19/epidemiology; COVID-19/immunology; COVID-19/virology; COVID-19 Vaccines/adverse effects; Helminthiasis/epidemiology; Helminthiasis/parasitology; Helminths/pathogenicity; Host-Pathogen Interactions; Humans; Immunization Schedule; SARS-CoV-2/pathogenicity; Treatment Outcome; Vaccination

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Research Design / Clinical Trials as Topic / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Vaccine Development / Helminthiasis / Helminths Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Country/Region as subject: Africa Language: English Journal: Nat Immunol Journal subject: Allergy and Immunology Year: 2022 Document Type: Article Affiliation country: S41590-021-01116-8

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google